This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Atara Biotherapeutics, Inc.
Drug Names(s): WT1 CTL, WT1-sensitized T cells, WT1-specific cytotoxic T cells
The WT1-CTL product candidate is being developed as a potential third party, donor-derived, off-the-shelf T-cell product candidate designed to target and destroy cancer cells that overexpress WT1.
The sponsor's T-cell product candidates are made from T-cells collected from the blood of donors and exposed to certain antigens. The resulting activated T-cells are expanded, characterized and stored for future therapeutic use in an appropriate partially human leukocyte antigen matched patient.
Atara and Memorial Sloan-Kettering Cancer Center
In September 2014, Atara Biotherapeutics entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK); under which, Atara has the right to license (pursuant to a negotiated form of license agreement) the exclusive worldwide rights to the three clinical stage T-cell programs of MSK. The initial option period is for 12 months, with extensions available to extend the term up to 27 months at the option of Atara.
Under the terms of the option agreement, Atara is obligated to use reasonable efforts to prepare a request to be submitted to the US Food and Drug Administration (the FDA) regarding a meeting to discuss pivotal trials for one of the clinical stage T-cell programs. In exchange for the exclusive option, Atara paid MSK $1,250,000 in cash and issued 59,761 shares of the Company's common stock to MSK. Atara estimated the fair value of the common stock issued to MSK to be $750,000. This...See full deal structure in Biomedtracker
Partners: Memorial Sloan-Kettering Cancer Center
Additional information available to subscribers only: